| abstract |
The invention relates to a taxane pharmaceutical formulation to be administered to mammals, preferably humans, comprising two composition which are combined prior to administration, such as to form a transparent solution free of precipitates and essentially free of foam, whereby said compositions comprise a solid taxane composition and a composition for solubilising said solid taxane composition, containing a surfactant and an anti-foaming agent. The invention also relates to a kit for the injectable taxane formulation, containing a pre-filled syringe, and to a pharmaceutical taxane perfusion solution. |